|Bid||3.7800 x 1100|
|Ask||3.9500 x 1000|
|Day's Range||3.7400 - 4.1450|
|52 Week Range||1.7920 - 8.3500|
|Beta (3Y Monthly)||1.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 13, 2019 - May 17, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.60|
NEWTOWN SQUARE, Pa., April 16, 2019 -- Kaskela Law LLC is investigating Evofem Biosciences, Inc. (“Evofem” or the “Company”) (NASDAQ: EVFM) on behalf of the Company’s.
INCLINE VILLAGE, Nev., April 11, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (PDLI) announces that it has entered into a securities purchase agreement with Evofem Biosciences, Inc. ("Evofem") (EVFM), pursuant to which it will invest a total of up to $60 million in a private placement of securities. The transaction is expected to have two tranches. The first tranche comprises $30 million, which was provided today. In addition, PDL has the right to invest an additional $30 million in a second tranche alongside two existing Evofem shareholders, which have the right to invest up to $10 million each.
"Successful completion of this financing should enable us to execute our strategy with confidence and to ensure the successful launch of Amphora in 2020 as a novel, hormone-free, woman-controlled contraceptive, if approved by the FDA," said Saundra Pelletier, CEO of Evofem Biosciences.
Evofem Biosciences is raising $80m as it tries to secure US regulatory approval for the first innovative form of contraceptive for almost two decades, a hormone-free alternative to the pill. PDL Biopharma, a Nasdaq-listed investment firm, will lead the round, buying $60m of newly issued stock in the publicly traded Evofem at $4.50, about $1 a share more than the closing price on Wednesday. Existing investors Invesco Asset Management and Woodford Investment Management are each investing $10m in newly issued stock.
SAN DIEGO, Calif. , April 3, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, announced today it will present at the 18 th Annual Needham Healthcare ...
SAN DIEGO , March 12, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company, announced today it will ...
Positive Phase 3 Amphora Results Enabling NDA Submission Management to Host Conference Call at 11:00 a.m. EST SAN DIEGO , March 1, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" ...
-- Conference Call Scheduled for 11:00 a.m. EST -- SAN DIEGO , Feb. 19, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a conference call to discuss financial results and business ...
NEW YORK, NY / ACCESSWIRE / January 7, 2019 / Traders News Source, aleading independent equity research and corporate access firm focused on smalland mid-cap public companies is issuing a comprehensive ...
The Company recently reported that its Phase 3 trial evaluating Amphora® for the prevention of pregnancy met its primary endpoint, and plans to resubmit the Amphora NDA in the second quarter of 2019.
NEW YORK, NY / ACCESSWIRE / December 18, 2018 / Evofem Biosciences had a day of gains on Monday after announcing positive results on its hormone free birth control gel. Shares of Diffusion Pharmaceuticals were in the red despite announcing that the company was awarded a patent for the use of its breakthrough drug, trans sodium crocetinate (TSC), in conjunction with Tissue Plasminogen Activator (tPA) for the treatment of stroke.
On Monday 12/17/2018, Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI), Diffusion Pharmaceuticals Inc. (DFFN), Evofem Biosciences, Inc. (EVFM) and Synergy Pharmaceuticals Inc. (SGYP) are presenting investors with upside opportunity ahead of Christmas and the 2019 New Year. Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI) a company you may have not heard of yet, has seen a strong month of bullish trading and shares of the company have climbed by as much as 31% over the last 30 days. The Company has been focusing on a growth strategy with key announcements which continue to build new interest.
Evofem Biosciences Inc said on Monday its hormone-free birth control gel met the main goal in a late-stage study. The company said it plans to resubmit the marketing application for Amphora in the second ...
SAN DIEGO, Dec. 17, 2018 /PRNewswire/ -- Evofem Biosciences, Inc. (EVFM) ("Evofem" or the "Company") today announced that its Phase 3 clinical trial of Amphora® for the prevention of pregnancy, AMPOWER, successfully met its primary endpoint. AMPOWER assessed the efficacy, safety and subject satisfaction with Amphora in approximately 1,400 healthy women aged 18-35 years at 112 centers in the U.S. The primary endpoint of the study was the pregnancy rate over seven cycles of use (one cycle = 21-35 days) as assessed by the Kaplan-Meier statistical method.
Assuming positive results, Evofem expects to re-submit the Amphora New Drug Application in the first half of 2019 which, if approved by the FDA, would position the Company to commercialize Amphora in January 2020 as the first and only non-hormonal, on-demand prescription birth control method in the U.S. Evofem's management team will host one-on-one meetings with investors during the conference.
Amphora is an investigational, first-in-class MVP-R designed to give a woman control over some of the most intimate issues of her life and health. This non-hormonal, non-systemic vaginal gel is being developed for woman-controlled birth control as well as prevention of certain sexually transmitted infections (STIs).
Management to Host Conference Call at 11:00 a.m. EST SAN DIEGO , Nov. 7, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), today reported financial ...
- Currently 16.5M women in the U.S. are not using birth control and want to avoid pregnancy - Amphora®, a Multipurpose Vaginal pH Regulator product candidate, top-line Phase 3 data expected by YE 2018 ...
-- Conference Call Scheduled for 11:00 a.m. EST -- SAN DIEGO , Oct. 24, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem"), a clinical-stage biopharmaceutical company committed ...
SAN DIEGO, Oct. 9, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, announced details of two oral presentations of data related to their lead product, Amphora®, a Multipurpose Vaginal pH Regulator (MVP-R) in late-stage development for prevention of pregnancy and prevention of urogenital transmission of chlamydia in women, at the 2018 American Society for Reproductive Medicine (ASRM) Annual Congress earlier today. "The data presented at ASRM, including patient satisfaction data from the AMP001 Phase 3 trial and important Phase 1 data on Amphora's ability to regulate vaginal pH, support the continuation of our robust clinical development initiatives," said Brandi Howard, PhD, Senior Vice President of Global Clinical Development Medical Affairs of Evofem Biosciences.